[go: up one dir, main page]

RU2427573C2 - Новые производные бензимидазола в качестве ингибиторов ваниллоидного рецептора 1 (vr1) - Google Patents

Новые производные бензимидазола в качестве ингибиторов ваниллоидного рецептора 1 (vr1) Download PDF

Info

Publication number
RU2427573C2
RU2427573C2 RU2008122404/04A RU2008122404A RU2427573C2 RU 2427573 C2 RU2427573 C2 RU 2427573C2 RU 2008122404/04 A RU2008122404/04 A RU 2008122404/04A RU 2008122404 A RU2008122404 A RU 2008122404A RU 2427573 C2 RU2427573 C2 RU 2427573C2
Authority
RU
Russia
Prior art keywords
pain
benzimidazol
ethyl
acetamide
chronic
Prior art date
Application number
RU2008122404/04A
Other languages
English (en)
Other versions
RU2008122404A (ru
Inventor
Евгени БЕСИДСКИ (SE)
Евгени Бесидски
Эндрю ГРИФФИН (CA)
Эндрю Гриффин
Дени ЛАБРЕККЕ (CA)
Дени ЛАБРЕККЕ
Шон ДЖОНСТОУН (CA)
Шон Джонстоун
Пол ДЖОНС (CA)
Пол ДЖОНС
Ингер КЕРС (SE)
Ингер Керс
Мартин НЮЛЁФ (SE)
Мартин НЮЛЁФ
Карин СКОГХОЛЬМ (SE)
Карин СКОГХОЛЬМ
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38189102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2427573(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2008122404A publication Critical patent/RU2008122404A/ru
Application granted granted Critical
Publication of RU2427573C2 publication Critical patent/RU2427573C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение относится к соединению, выбранному из N-((1S)-1-{4-[2-фтор-1-(фторметил)этокси]фенил}этил)-2-(7-нитро-1Н-бензимидазол-1-ил)ацетамида, 2-(7-нитро-1Н-бензимидазол-1-ил)-N-{1-[6-(2,2,3,3-тетрафторпропокси)пиридин-3-ил]этил}ацетамида, N-[1-(4-тpeт-бутилфенил)этил]-2-(6,7-дифтор-1H-бензимидазол-1-ил)ацетамида и N-[(1S)-1-(4-трет-бутилфенил)этил]-2-(6,7-дифтор-1Н-бензимидазол-1-ил)ацетамида. Также изобретение относится к применению указанных соединений в изготовлении лекарственного средства. Технический результат: получены новые соединения, полезные для лечения расстройств, опосредованных VR1 (ваниллоидный рецептор 1), и/или для лечения острых и хронических болевых расстройств. 2 н. и 4 з.п. ф-лы, 5 табл.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073

Claims (6)

1. Соединение, выбранное из:
N-((1S)-1-{4-[2-фтор-1-(фторметил)этокси]фенил}этил)-2-(7-нитро-1Н-бензимидазол-1-ил)ацетамида,
2-(7-нитро-1Н-бензимидазол-1-ил)-N-{1-[6-(2,2,3,3-тетрафторпропокси)пиридин-3-ил]этил}ацетамида,
N-[1-(4-трет-бутилфенил)этил]-2-(6,7-дифтор-1Н-бензимидазол-1-ил)ацетамида и
N-[(1S)-1-(4-трет-бутилфенил)этил]-2-(6,7-дифтор-1Н-бензимидазол-1-ил)ацетамида.
2. Соединение по п.1, представляющее собой N-[1-(4-трет-бутилфенил)этил]-2-(6,7-дифтор-1Н-бензимидазол-1-ил)ацетамид.
3. Соединение по п.1, представляющее собой N-[(1S)-1-(4-тpeт-бутилфенил)этил]-2-(6,7-дифтор-1Н-бензимидазол-1-ил)ацетамид.
4. Соединение по любому из пп.1-3 для ингибирования ваниллоидного рецептора 1 (VR1).
5. Соединение по любому из пп.1-3 для лечения острой и хронической боли.
6. Применение соединений по любому из пп.1-3 в изготовлении лекарственного средства для лечения расстройств, опосредованных VR1 (ваниллоидный рецептор 1), и/или для лечения острых и хронических болевых расстройств, таких как острая или хроническая невропатическая боль, острая или хроническая ноцицептивная боль и острая или хроническая воспалительная боль; и/или респираторных заболеваний; артрита; остеоартрита; ревматоидного артрита; фибромиалгии; поясничной боли; послеоперационной боли; висцеральных болей, таких как хроническая боль в области таза; цистита; синдрома раздраженного кишечника (IBS); панкреатита; ишемии, ишиаса, диабетической невропатии, рассеянного склероза, интерстициального цистита и/или боли, связанной с интерстициальным циститом; невропатии при ВИЧ; астмы; кашля; и/или воспалительного кишечного заболевания (IBD); заболевания гастроэзофагеальный рефлюкс (GERD); боли и других признаков и симптомов, ассоциированных с псориазом; боли и других признаков и симптомов, ассоциированных с раком; ожирения; рвоты; энуреза; и/или гиперактивного мочевого пузыря, включая признаки и/или симптомы, относящиеся к указанным заболеваниям.
RU2008122404/04A 2005-12-23 2006-12-21 Новые производные бензимидазола в качестве ингибиторов ваниллоидного рецептора 1 (vr1) RU2427573C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75360405P 2005-12-23 2005-12-23
US60/753,604 2005-12-23

Publications (2)

Publication Number Publication Date
RU2008122404A RU2008122404A (ru) 2010-01-27
RU2427573C2 true RU2427573C2 (ru) 2011-08-27

Family

ID=38189102

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008122404/04A RU2427573C2 (ru) 2005-12-23 2006-12-21 Новые производные бензимидазола в качестве ингибиторов ваниллоидного рецептора 1 (vr1)

Country Status (21)

Country Link
US (2) US7618993B2 (ru)
EP (1) EP1966156B1 (ru)
JP (1) JP2009521431A (ru)
KR (1) KR20080080212A (ru)
CN (1) CN101389610B (ru)
AR (1) AR058705A1 (ru)
AT (1) ATE538101T1 (ru)
AU (1) AU2006327320B2 (ru)
BR (1) BRPI0620410A2 (ru)
CA (1) CA2634804A1 (ru)
EC (1) ECSP088584A (ru)
ES (1) ES2377661T3 (ru)
IL (1) IL191753A0 (ru)
NO (1) NO20083246L (ru)
NZ (1) NZ569923A (ru)
RU (1) RU2427573C2 (ru)
TW (1) TW200736227A (ru)
UA (1) UA96277C2 (ru)
UY (1) UY30048A1 (ru)
WO (1) WO2007073303A2 (ru)
ZA (1) ZA200805162B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
UY30048A1 (es) * 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
WO2009054983A1 (en) * 2007-10-24 2009-04-30 Merck & Co., Inc. Heterocycle amide t-type calcium channel antagonists
NZ587771A (en) 2008-04-18 2011-05-27 Dae Woong Pharma Novel benzoxazine benzimidazole derivatives, pharmaceutical composition comprising same, and a use thereof
DE112011102008B4 (de) 2010-06-15 2022-04-21 Merck Patent Gmbh Metallkomplexe
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
WO2016055582A1 (en) * 2014-10-08 2016-04-14 Thomas Helledays Stiftelse För Medicinsk Forskning Heterocyclic compounds as dctpp1 modulators
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
JP2018052817A (ja) * 2015-01-21 2018-04-05 大日本住友製薬株式会社 新規ベンズイミダゾール誘導体およびその医薬用途
US11186564B2 (en) 2016-08-04 2021-11-30 Sunovion Pharmaceuticals Inc. Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
EP3908574A4 (en) * 2019-01-08 2022-10-26 Neomed Institute CRYSTALLINE FORMS OF (S)-2-(7-CYANO-1H-BENZIMIDAZOL-1YL)-N-{1-[4-(1-CYANO-1-METHYLETHYL)PHENYL]ETHYL}ACETAMIDE
CR20220160A (es) 2019-09-16 2022-06-16 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
CA3218090A1 (en) 2021-05-10 2022-11-17 Magnus HALLDIN New formulations and uses
GB202217159D0 (en) 2022-11-16 2022-12-28 AlzeCure Pharma AB New use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU691090A3 (ru) * 1975-09-16 1979-10-05 Хиноин Дьедьсер Еш Ведьесети Термекек Дьяра Рт (Фирма) Способ получени производных бензимидазола
WO2004100865A2 (en) * 2003-05-16 2004-11-25 Astrazeneca Ab New benzimidazole derivatives
WO2005021539A1 (en) * 2003-09-03 2005-03-10 Pfizer Japan, Inc. Benzimidazolone compounds having 5-ht4 receptor agonistic activity

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1186504A (en) 1966-10-15 1970-04-02 Fisons Pest Control Ltd Substituted Heterocyclic Compounds
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
BE793718A (fr) 1972-01-07 1973-07-05 Merck & Co Inc Aminobenzimidazoles
DE3347290A1 (de) * 1983-12-28 1985-07-11 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-phenyl-imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4738981A (en) * 1984-11-13 1988-04-19 Warner-Lambert Substituted trans-1,2-diaminocyclohexyl amide compounds
JPH06759B2 (ja) 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
DE4309969A1 (de) 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
EA002357B1 (ru) 1995-12-28 2002-04-25 Фудзисава Фармасьютикал Ко., Лтд. Производные бензимидазола
GB9713484D0 (en) 1997-06-27 1997-09-03 Smithkline Beecham Plc Neuroprotective vanilloid compounds
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
BR0013143A (pt) 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
EP1278744A1 (en) 2000-05-05 2003-01-29 Millenium Pharmaceuticals, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
MXPA02010763A (es) 2000-06-14 2003-03-10 Warner Lambert Co Heterociclicos biciclos-6,5 fusionados.
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JP4929472B2 (ja) 2000-08-22 2012-05-09 小野薬品工業株式会社 カルボン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
ITTO20010110A1 (it) 2001-02-08 2002-08-08 Rotta Research Lab Nuovi derivati benzamidinici dotati di attivita' anti-infiammatoria ed immunosoppressiva.
GB0105895D0 (en) 2001-03-09 2001-04-25 Smithkline Beecham Plc Novel compounds
SE0101387D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
GB0110901D0 (en) 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
TWI239942B (en) 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
CA2445653A1 (en) 2001-06-11 2002-12-19 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
AU2002325381A1 (en) 2001-07-31 2003-02-24 Bayer Healthcare Ag Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
TWI283665B (en) 2001-09-13 2007-07-11 Smithkline Beecham Plc Novel urea compound, pharmaceutical composition containing the same and its use
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
PL373484A1 (en) 2001-12-10 2005-09-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0130550D0 (en) 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel compounds
EP2033953A1 (en) 2002-02-15 2009-03-11 Glaxo Group Limited Vanilloid receptor modulators
US20030158188A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
NZ552283A (en) 2002-06-20 2008-07-31 Biovitrum Ab Publ New compounds useful for the treatment of obesity, type II diabetes and CNS disorders
GB0221157D0 (en) 2002-09-12 2002-10-23 Glaxo Group Ltd Novel treatment
WO2004024710A1 (en) 2002-09-13 2004-03-25 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
US7582761B2 (en) * 2002-10-17 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1736465A4 (en) * 2004-03-31 2009-06-17 Ajinomoto Kk ANILINE DERIVATIVES
SE0402284D0 (sv) * 2004-09-21 2004-09-21 Astrazeneca Ab New heterocyclic amides
UY30048A1 (es) * 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
RU2424233C2 (ru) * 2006-06-29 2011-07-20 Ф.Хоффманн-Ля Рош Аг Производные бензимидазола, методы их получения, применение их в качестве агонистов фарнезоид-х-рецептора (fxr) и содержащие их фармацевтические препараты
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU691090A3 (ru) * 1975-09-16 1979-10-05 Хиноин Дьедьсер Еш Ведьесети Термекек Дьяра Рт (Фирма) Способ получени производных бензимидазола
WO2004100865A2 (en) * 2003-05-16 2004-11-25 Astrazeneca Ab New benzimidazole derivatives
WO2005021539A1 (en) * 2003-09-03 2005-03-10 Pfizer Japan, Inc. Benzimidazolone compounds having 5-ht4 receptor agonistic activity

Also Published As

Publication number Publication date
CN101389610A (zh) 2009-03-18
EP1966156B1 (en) 2011-12-21
ECSP088584A (es) 2008-07-30
IL191753A0 (en) 2008-12-29
WO2007073303A3 (en) 2007-08-30
UY30048A1 (es) 2007-07-31
US7618993B2 (en) 2009-11-17
WO2007073303A2 (en) 2007-06-28
CA2634804A1 (en) 2007-06-28
BRPI0620410A2 (pt) 2011-11-08
NZ569923A (en) 2011-04-29
KR20080080212A (ko) 2008-09-02
RU2008122404A (ru) 2010-01-27
AU2006327320B2 (en) 2009-12-10
US20080171770A1 (en) 2008-07-17
CN101389610B (zh) 2011-12-07
JP2009521431A (ja) 2009-06-04
NO20083246L (no) 2008-09-11
ATE538101T1 (de) 2012-01-15
US8168668B2 (en) 2012-05-01
ES2377661T3 (es) 2012-03-29
AU2006327320A1 (en) 2007-06-28
AR058705A1 (es) 2008-02-20
US20100286202A1 (en) 2010-11-11
HK1121755A1 (en) 2009-04-30
UA96277C2 (en) 2011-10-25
TW200736227A (en) 2007-10-01
ZA200805162B (en) 2009-11-25
EP1966156A2 (en) 2008-09-10

Similar Documents

Publication Publication Date Title
RU2427573C2 (ru) Новые производные бензимидазола в качестве ингибиторов ваниллоидного рецептора 1 (vr1)
RU2350611C1 (ru) Производные фосфонооксихиназолина и их фармацевтическое применение
RU2458920C2 (ru) Новые соединения
UA96764C2 (ru) Производные бензимидазола, полезные в лечении расстройств, связанных с рецептором trpvl
RU2434853C2 (ru) Новые конденсированные производные пиррола
RU2013128544A (ru) Способы лечения с использованием селективных ингибиторов dcl-2
CA2601508A1 (en) Cyclopropanecarboxamide derivatives
CA2600409A1 (en) Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds
EA200601266A1 (ru) Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
RU2011149360A (ru) Замещенные фенилмочевины и фениламиды в качестве лигандов ваниллоидных рецепторов
JP2010510202A5 (ru)
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
RU2009135621A (ru) Хинолиновые производные для лечения воспалительных заболеваний
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
EA201070422A1 (ru) Производные оксадиазола
JP2008110984A5 (ru)
RU2389722C2 (ru) Варианты имидазола в качестве модуляторов рецептора гамма-аминомасляной кислоты (gaba) для лечения желудочно-кишечных (жк) расстройств
JP2009530282A5 (ru)
SE0403006D0 (sv) New compounds
EA200701705A1 (ru) Антагонисты рецепторы глюкагона, получение и терапевтическое применение
CA2610354A1 (en) Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
JP2013506674A5 (ru)
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
CA2587149A1 (en) Substituted n-sulfonylaminobenzyl-2-phenoxyacetamide compounds

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20141222